Efficacy of enrofloxacin in a mouse model of sepsis

Journal of the American Association for Laboratory Animal Science

Volumn 53, Issue 4, 2014, Pages 381-386

  Slate, Andrea R ^a   Bandyopadhyay, Sheila ^b   Francis, Kevin P ^d   Papich, Mark G ^e   Karolewski, Brian ^c   Hod, Eldad A ^b   Prestia, Kevin A ^b,c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b Laboratory of Transfusion Biology Department of Pathology and Cell Biology College of Physicians and Surgeons ^*  (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d PERKINELMER INC   (United States)

^e NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DRINKING WATER; ENROFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BIOLUMINESCENCE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; ENTEROPATHOGENIC ESCHERICHIA COLI; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; RAT; SEPSIS;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FLUOROQUINOLONES; MALE; MICE; SEPSIS;

EID: 84905508188     PISSN: 15596109     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303-1310. (Pubitemid 32641789)
2. Aucoin D. 2007. Target: the antimicrobial reference guide to effective treatment, 3rd ed. Port Huron (MI): North American Compendiums.
3. Barbier M, Damron FH, Bielecki P, Suárez-Diez M, Puchałka J, Albertí S, Martins dos Santos V, Goldberg JB. 2014. From the environment to the host: re-wiring of the transcriptome of Pseudomonas aeruginosa from 22°C to 37°C. PloS One 9:e89941.
4. Black-Schultz L, Coatney RW, Warnick CL, Swif B. 1997. Lack of reactivation of shigellosis in naturally infected enrofloxacin-treated cynomolgus monkeys after exogenous immunosuppression. Lab Anim Sci 47:602-605.
5. Blondeau JM, Borsos S, Blondeau L, Blondeau B. 2012. In vitro killing of Escherichia coli, Staphylococcus pseudintermedius and Pseudomonas aeruginosa by enrofloxacin in combination with its active metabolite ciprofloxacin using clinically relevant drug concentrations in the dog and cat. Vet Microbiol 155:284-290.
6. Bone RC. 1993. Gram-negative sepsis: a dilemma of modern medicine. Clin Microbiol Rev 6:57-68. (Pubitemid 23055194)
7. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein R, Sibbald WJ. 1992. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644-1655.
8. Bregante MA, Saez P, Aramayona J, Fraile L, Garcia M, Solans C. 1999. Comparative pharmacokinetics of enrofloxacin in mice, rats, rabbits, sheep, and cows. Am J Vet Res 60:1111-1116. (Pubitemid 29438937)
9. Brown SA. 1996. Fluoroquinolones in animal health. J Vet Pharmacol Ther 19:1-14. (Pubitemid 26096341)
10. Burns-Guydish SM, Olomu IN, Zhao H, Wong RJ, Stevenson DK, Contag CH. 2005. Monitoring age-related susceptibility of young mice to oral Salmonella enterica serovar Typhimurium infection using an in vivo murine model. Pediatr Res 58:153-158. (Pubitemid 40967447)
11. Carpenter JW. 2013. Exotic animal formulary, 4th ed. St Louis (MO): Elsevier Saunders.
12. Chun MK, Choi HK. 2004. Preparation and characterization of enrofloxacin-carbopol complex in aqueous solution. Arch Pharm Res 27:670-675.
13. Close DM, Xu T, Sayler GS, Ripp S. 2011. In vivo bioluminescent imaging (BLI): noninvasive visualization and interrogation of biological processes in living animals. Sensors (Basel) 11:180-206.
14. Cohen J. 2002. The immunopathogenesis of sepsis. Nature 420:885-891. (Pubitemid 36019643)
15. Cox SK, Cottrell M, Smith L, Papich M, Frazier D, Bartges J. 2004. Allometric analysis of ciprofloxacin and enrofloxacin pharmacokinetics across species. J Vet Pharmacol Ther 27:139-146. (Pubitemid 38859447)
16. Davis JL, Foster D, Papich M. 2007. Pharmacokinetics and tissue distribution of enrofloxacin and its active metabolite ciprofloxacin in calves. J Vet Pharmacol Ther 30:564-571. (Pubitemid 350060568)
17. Deitch EA. 1998. Animal models of sepsis and shock: a review and lessons learned. Shock 9:1-11. (Pubitemid 128463868)
18. Dudley MN. 1991. Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones. Am J Med 91:S45-S50.
19. Elmas M, Yazar E, Uney K, Tras B. 2008. Pharmacokinetics of enrofloxacin and flunixin meglumine and interactions between both drugs after intravenous co-administration in healthy and endotoxaemic rabbits. Vet J 177:418-424. (Pubitemid 351894529)
20. Felt S, Papich MG, Howard A, Long T, McKeon G, Torreilles S, Green S. 2013. Tissue distribution of enrofloxacin in African clawed frogs (Xenopus laevis) after intramuscular and subcutaneous administration. J Am Assoc Lab Anim Sci 52:186-188.
21. Foucault ML, Thomas L, Goussard S, Branchini B, Grillot-Courvalin C. 2010. In vivo bioluminescence imaging for the study of intestinal colonization by Escherichia coli in mice. Appl Environ Microbiol 76:264-274.
22. Goelz MF, Thigpen JE, Mahler J, Rogers WP, Locklear J, Weigler BJ, Forsythe DB. 1996. Efficacy of various therapeutic regimens in eliminating Pasteurella pneumotropica from the mouse. Lab Anim Sci 46:280-285. (Pubitemid 126492182)
23. Hamblin MR, O'Donnell DA, Murthy N, Contag CH, Hasan T. 2002. Rapid control of wound infections by targeted photodynamic therapy monitored by in vivo bioluminescence imaging. Photochem Photobiol 75:51-57.
24. Harkness JE, Wagner JE. 1989. The biology and medicine of rabbits and rodents, 3rd ed. Philadelphia (PA): Lea and Febiger.
25. Howard AM, Papich MG, Felt SA, Long CT, McKeon GP, Bond ES, Torreilles SL, Luong RH, Green SL. 2010. The pharmacokinetics of enrofloxacin in adult African clawed frogs (Xenopus laevis). J Am Assoc Lab Anim Sci 49:800-804.
26. Idowu O, Peggins J, Cullison R, Bredow JV. 2010. Comparative pharmacokinetics of enrofloxacin and ciprofloxacin in lactating dairy cows and beef steers following intravenous administration of enrofloxacin. Res Vet Sci 89:230-235.
27. Idowu OR, Peggins JO. 2004. Simple, rapid determination of enrofloxacin and ciprofloxacin in bovine milk and plasma by high-performance liquid chromatography with fluorescence detection. J Pharm Biomed Anal 35:143-153. (Pubitemid 38368869)
28. Institute for Laboratory Animal Research. 2011. Guide for the care and use of laboratory animals, 8th ed. Washington (DC): National Academies Press.
29. Kadurugamuwa JL, Francis KP. 2008. Bioluminescent imaging of bacterial biofilm infections in vivo. Methods Mol Biol 431:225-239.
30. Kadurugamuwa JL, Sin LV, Yu J, Francis KP, Kimura R, Purchio T, Contag PR. 2003. Rapid direct method for monitoring antibiotics in a mouse model of bacterial biofilm infection. Antimicrob Agents Chemother 47:3130-3137. (Pubitemid 37229568)
31. Liu P, Müller M, Derendorf H. 2002. Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents 19:285-290. (Pubitemid 34308976)
32. Macy JD, Weir EC, Compton SR, Shlomchik MJ, Brownstein DG. 2000. Dual infection with Pneumocystis carinii and Pasteurella pneumotropica in B cell-deficient mice: diagnosis and therapy. Comp Med 50:49-55. (Pubitemid 30190584)
33. Maddison JE, Page SW, Church DB. 2008. Small animal clinical pharmacology, 2nd ed. Philadelphia (PA): Saunders.
34. Matsumiya LC, Lavoie C. 2003. An outbreak of Pasteurella pneumotropica in genetically modified mice: treatment and elimination. Contemp Top Lab Anim Sc 42:26-28. (Pubitemid 37102011)
35. McKellar QA, Sanchez Bruni S, Jones D. 2004. Pharmacokinetic- pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine. J Vet Pharmacol Ther 27:503-514. (Pubitemid 39665136)
36. Meinen JB, McClure J, Rosin E. 1995. Pharmacokinetics of enrofloxacin in clinically normal dogs and mice and drug pharmacodynamics in neutropenic mice with Escherichia coli and staphylococcal infections. Am J Vet Res 56:1219-1224.
37. Messenger KM, Papich MG, Blikslager A. 2012. Distribution of enrofloxacin and its active metabolite, using an in vivo ultrafiltration sampling technique after the injection of enrofloxacin to pigs. J Vet Pharmacol Ther 35:452-459.
38. Moore LJ, Moore FA, Todd SR, Jones SL, Turner KL, Bass BL. 2010. Sepsis in general surgery: the 2005-2007 national surgical quality improvement program perspective. Arch Surg 145: 695-700.
39. Nunamaker EA, Artwohl JE, Anderson RJ, Fortman JD. 2013. Endpoint refinement for total body irradiation of C57BL/6 mice. Comp Med 63:22-28.
40. Ogino T, Arai T. 2007. Pharmacokinetic interactions of flunixin meglumine and enrofloxacin in ICR mice. Exp Anim 56:79-84. (Pubitemid 46711791)
41. Papich MG, Van Camp S, Cole J, Whitacre M. 2002. Pharmacokinetics and endometrial tissue concentrations of enrofloxacin and the metabolite ciprofloxacin after IV administration of enrofloxacin to mares. J Vet Pharmacol Ther 25:343-350. (Pubitemid 35365587)
42. Papich MG, Riviere JE. 2009. Fluoroquinolone antimicrobial drugs, p 983-1012. In: Riviere J, Papich MG editors. Veterinary pharmacology and therapeutics. Ames (IA): Wiley-Blackwell Publishing.
43. Petritz OA, Guzman DS-M, Wiebe VJ, Papich MG. 2013. Stability of 3 commonly compounded extemporaneous enrofloxacin suspensions for oral administration to exotic animals. J Am Vet Med Assoc 243:85-90.
44. Pisharath HR, Cooper TK, Brice AK, Cianciolo RE, Pistorio AL, Wachtman LM, Mankowski JL, Newcomer CE. 2005. Septicemia and peritonitis in a colony of common marmosets (Callithrix jacchus) secondary to Klebsiella pneumoniae infection. Contemp Top Lab Anim Sc 44:35-37. (Pubitemid 41569242)
45. Plumb DC. 2011. Plumb's veterinary drug handbook, 7th ed. Ames (IA): Wiley-Blackwell.
46. Quesenberry K, Carpenter JW. 2011. Ferrets, rabbits, and rodents: clinical medicine and surgery, 3rd ed. Philadelphia (PA): Saunders.
47. Rocchetta HL, Boylan C, Foley J, Iversen P, LeTourneau D, McMillian C, Contag P, Jenkins D, Parr T. 2001. Validation of a noninvasive, real-time imaging technology using bioluminescent Escherichia coli in the neutropenic mouse thigh model of infection. Antimicrob Agents Chemother 45:129-137. (Pubitemid 32039104)
48. Rowland NE. 2007. Food or fluid restriction in common laboratory animals: balancing welfare considerations with scientific inquiry. Comp Med 57:149-160. (Pubitemid 47065782)
49. Ueno Y, Shimizu R, Nozu R, Takahashi S, Yamamoto M, Sugiyama F, Takakura A, Itoh T, Yagami K-i. 2002. Elimination of Pasteurella pneumotropica from a contaminated mouse colony by oral administration of enrofloxacin. Exp Anim 51: 401-405. (Pubitemid 135695693)
50. United States Pharmacopeial Convention. 2014. The United States Pharmacoepia 37. Rockville (MD): US Pharmacopeia.
51. Vuong C, Kocianova S, Yu J, Kadurugamuwa JL, Otto M. 2008. Development of real-time in vivo imaging of device-related Staphylococcus epidermidis infection in mice and influence of animal immune status on susceptibility to infection. J Infect Dis 198:258-261. (Pubitemid 352019291)
52. Wiuff C, Lykkesfeldt J, Aarestrup FM, Svendsen O. 2002. Distribution of enrofloxacin in intestinal tissue and contents of healthy pigs after oral and intramuscular administrations. J Vet Pharmacol Ther 25:335-342. (Pubitemid 35365586)
53. Xiong YQ, Willard J, Kadurugamuwa JL, Yu J, Francis KP, Bayer AS. 2005. Real-time in vivo bioluminescent imaging for evaluating the efficacy of antibiotics in a rat Staphylococcus aureus endocarditis model. Antimicrob Agents Chemother 49:380-387. (Pubitemid 40065815)